| Followers | 258 |
| Posts | 19732 |
| Boards Moderated | 0 |
| Alias Born | 10/03/2004 |
Wednesday, June 09, 2010 5:34:21 PM
Oh, you are talking about clinical trials? Phase-0/1 through Phase 3 are not "FDA studies". They are studies that follow an IND application and precede an NDA. Each Phase is reviewed by the FDA before advancing to the next phase, but there are no "FDA studies". Unless you are referring to all studies leading to FDA filings and review, then NNVC is currently in "FDA studies", which sort of makes your claim completely false.
Another complete falsehood is your half million share number. The most recent conversion was a few thousand over 400K shares, not nearly half a million. Further your statement of such a number entering the float assumes that Seaside88 is selling all the shares every 10 days. The current pattern, if you include the daily short count, indicates that the downward selling pressure doesn't come from Seaside88 but from shorting strategists exploiting the potential for Seaside88 selling. In the most recent OTC Short interest publication, which covers the time period for two conversions, the shares short are 2,199,923 an increase of more than 9%. That hardly indicates a significant number of new shares entering the float. It instead shows a significant selling pressure from an increase of more than 200K borrowed shares entering the float.
Of course, I don't understand any of this because it's way beyond the knowledge of a simple Lib Arts teacher, and on top of that my TA sucks, so what do I know?
Another complete falsehood is your half million share number. The most recent conversion was a few thousand over 400K shares, not nearly half a million. Further your statement of such a number entering the float assumes that Seaside88 is selling all the shares every 10 days. The current pattern, if you include the daily short count, indicates that the downward selling pressure doesn't come from Seaside88 but from shorting strategists exploiting the potential for Seaside88 selling. In the most recent OTC Short interest publication, which covers the time period for two conversions, the shares short are 2,199,923 an increase of more than 9%. That hardly indicates a significant number of new shares entering the float. It instead shows a significant selling pressure from an increase of more than 200K borrowed shares entering the float.
Of course, I don't understand any of this because it's way beyond the knowledge of a simple Lib Arts teacher, and on top of that my TA sucks, so what do I know?
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
